URGN
UroGen Pharma Ltd.
$20.47
+$0.62(+3.12%)
51
Overall
40
Value
63
Tech
--
Quality
Market Cap
$933.61M
Volume
813.55K
52W Range
$3.42 - $21.71
Target Price
$33.75
Order:
Income Statement
| Metric | Trend | Chart | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | $8.2M | $1.1M | $18.0K | $11.8M | $48.0M | $64.4M | $82.7M | $90.4M | ||
| Total Revenue | $8.2M | $1.1M | $18.0K | $11.8M | $48.0M | $64.4M | $82.7M | $90.4M | ||
| COST OF GOODS SOLD | ||||||||||
| Cost of Revenue | $-600.0K | $-1.8M | -- | $1.0M | $5.2M | $7.7M | $9.4M | $8.9M | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | $7.6M | $-675.0K | $18.0K | $10.8M | $42.9M | $56.7M | $73.4M | $81.5M | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $27.5M | $76.5M | $109.5M | $138.5M | $140.3M | $135.7M | $138.9M | $178.3M | ||
| Research & Development | -- | $36.9M | $49.3M | $47.3M | $47.6M | $52.9M | $45.6M | $57.1M | ||
| Research Expense | -- | $36.9M | $49.3M | $47.3M | $47.6M | $52.9M | $45.6M | $57.1M | ||
| Selling, General & Administrative | $8.8M | $39.6M | $60.2M | $91.2M | $92.7M | $82.8M | $93.3M | $121.2M | ||
| Selling & Marketing Expenses | -- | -- | $60.2M | $1.0M | -- | -- | -- | -- | ||
| General & Administrative Expenses | $8.8M | $39.6M | $60.2M | $90.2M | $92.7M | $82.8M | $93.3M | $121.2M | ||
| Salaries & Wages | $18.7M | $-30.6M | $-30.0M | -- | -- | -- | $9.3M | $13.1M | ||
| Depreciation & Amortization | $-200.0K | $-400.0K | $-300.0K | $416.0K | $831.0K | $924.0K | $802.0K | $329.0K | ||
| Depreciation & Amortization | $-200.0K | $-400.0K | $-300.0K | $416.0K | $831.0K | $924.0K | $802.0K | $329.0K | ||
| Amortization | -- | -- | -- | -- | -- | -- | -- | $36.0K | ||
| Other Operating Expenses | $-27.5M | $-76.5M | $-109.5M | $-2.7M | $5.2M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-19.9M | $-77.2M | $-109.5M | $-126.7M | $-92.3M | $-79.0M | $-65.5M | $-96.8M | ||
| EBITDA | $-19.8M | $-75.1M | $-104.4M | $-124.7M | $-107.6M | $-97.8M | $-80.9M | $-111.6M | ||
| NON-OPERATING ITEMS | ||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | $8.4M | $14.7M | $12.5M | ||
| Interest Income Operating | $-31.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Intinc | -- | $1.6M | $4.6M | $2.0M | $212.0K | $1.0M | $3.5M | $8.9M | ||
| Net Non-Operating Interest Income/Expense | -- | $1.6M | $4.6M | $2.0M | $212.0K | $7.5M | $-14.7M | $-12.5M | ||
| Gain on Sale of Securities | -- | $-100.0K | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-168.0K | $224.0K | $-4.3M | -- | $153.0K | $-21.5M | $-838.0K | $229.0K | ||
| Other Special Charges | $168.0K | $-124.0K | $4.3M | -- | $-153.0K | $72.0K | $838.0K | $-229.0K | ||
| SPECIAL ITEMS | ||||||||||
| Special Income Charges | -- | -- | -- | $-1.0M | -- | -- | -- | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-20.0M | $-75.5M | $-105.1M | $-126.7M | $-109.4M | $-99.6M | $-83.6M | $-111.5M | ||
| Pre-Tax Income | $-20.0M | $-75.5M | $-105.1M | $-125.1M | $-109.4M | $-108.0M | $-98.3M | $-124.0M | ||
| INCOME TAX | ||||||||||
| Tax Provision | $19.0K | $125.0K | $257.0K | $3.4M | $1.4M | $1.8M | $3.9M | $2.8M | ||
| NET INCOME | ||||||||||
| Net Income | $-20.0M | $-75.7M | $-105.1M | $-128.5M | $-110.8M | $-109.8M | $-102.2M | $-126.9M | ||
| Net Income (Continuing Operations) | $-20.0M | $-75.7M | $-105.1M | $-128.5M | $-110.8M | $-109.8M | $-102.2M | $-126.9M | ||
| Net Income (Discontinued Operations) | $-20.0M | $-75.7M | $-105.1M | $-128.5M | $-110.8M | $-109.8M | $-102.2M | $-126.9M | ||
| Net Income (Common Stockholders) | $-20.0M | $-75.7M | $-105.1M | $-128.5M | $-110.8M | $-109.8M | $-102.2M | $-126.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | $-122.8M | ||
| TOTALS | ||||||||||
| Total Expenses | $26.9M | $74.7M | $109.5M | $139.5M | $145.5M | $143.4M | $148.2M | $187.2M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $9.7M | $15.8M | $20.5M | $21.8M | $22.3M | $22.8M | $28.8M | $42.9M | ||
| Average Shares Outstanding (Diluted) | $9.3M | $15.8M | $20.5M | $21.8M | $22.3M | $22.8M | $28.8M | $42.9M | ||
| Shares Outstanding | $13.8M | $20.5M | $21.2M | $22.3M | $22.7M | $23.4M | $34.1M | $46.1M | ||
| Basic EPS | -- | -- | -- | $-5.9 | $-4.96 | $-4.81 | $-3.55 | $-2.96 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-5.9 | $-4.96 | $-4.81 | $-3.55 | $-2.96 | ||
| Diluted EPS | $-2.14 | $-4.8 | $-5.12 | $-5.9 | $-4.96 | $-4.81 | $-3.55 | $-2.96 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-5.12 | -- | -- | -- | -- | -- | ||
| OTHER METRICS | ||||||||||
| Gain On Sale Of P P E | -- | $1.6M | -- | -- | -- | -- | -- | -- | ||
| Insurance And Claims | -- | -- | -- | -- | $5.2M | -- | -- | -- | ||
| Other Gand A | $8.8M | $39.6M | $60.2M | $90.2M | $92.7M | $82.8M | $93.3M | $121.2M | ||
| Otherunder Preferred Stock Dividend | $-825.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $-825.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $8.8M | $39.6M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | -- | -- | $60.2M | -- | -- | -- | -- | -- | ||
| Write Down | -- | -- | -- | $1.0M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | URGN | $20.47 | +3.1% | 813.55K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |